The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes

被引:18
|
作者
Thomas, M. C. [1 ]
机构
[1] Monash Univ, Dept Diabet, Melbourne, Vic, Australia
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2022年 / 128卷
关键词
Diabetic complications; Type; 2; diabetes; Cardiovascular disease; Diabetic foot disease; Diabetic eye disease; Metabolic-associated fatty liver disease; Diabetic kidney disease; CHRONIC KIDNEY-DISEASE; RISK-FACTORS; HEART-FAILURE; SICK FAT; MELLITUS; MORTALITY; METAANALYSIS; PREVALENCE; ALBUMINURIA; OUTCOMES;
D O I
10.1016/j.metabol.2021.154961
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is associated with an increased risk of cardiovascular disease, heart failure, chronic kidney disease, fatty liver disease, eye and foot disease. But equally, these conditions are associated with an increased risk of type 2 diabetes. Rather than being simply considered complications of diabetes, as exists within a 'pure' type 1 diabetes paradigm, both type 2 diabetes and its comorbidities are primarily caused by a failure to effi-ciently sequester excess energy leading to the accumulation of sick fat (adiposopathy). Type 2 diabetes is a symptom of a chronic disease complex, just as cardiovascular, renal, eye, foot and/or liver disease, are. In addition, each of these conditions feed forward so that dysfunction in one system accelerates dysfunction in another, partly through their shared pathogenesis and partly due dysfunction that follows in their wake. This review will explore the sticky, brittle conglomeration of CArdiac, Renal, Adipo-Metabolic, Eye and Liver disease (hereafter collectively known as CARAMEL disease) that is coincident in most patients with type 2 diabetes and contextualise the recent changes in diabetes guidelines that now specifically focus on identifying and aggressively managing these high-risk individuals with it. (c) 2021 Published by Elsevier Inc.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis
    Morrison, Amy E.
    Zaccardi, Francesco
    Khunti, Kamlesh
    Davies, Melanie J.
    LIVER INTERNATIONAL, 2019, 39 (03) : 557 - 567
  • [22] Update on Type 2 Diabetes as a Cardiovascular Disease Risk Equivalent
    Kuusisto, Johanna
    Laakso, Markku
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (02)
  • [23] Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
    Kruger, Davida F.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S43 - S52
  • [24] Cardiovascular disease in type 1 diabetes
    Sharma, Harish
    Lencioni, Mauro
    Narendran, Parth
    CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2019, 8 (01) : 28 - 34
  • [25] Temporal changes in risk of cardiovascular events in people with newly diagnosed type 2 diabetes with and without cardiovascular disease
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Malmborg, Morten
    Bonde, Anders N.
    Zareini, Bochra
    Mills, Elisabeth Helen Anna
    Vestergaard, Peter
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (02)
  • [26] Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria
    Heinrich, Niels Sondergaard
    von Scholten, Bernt Johan
    Reinhard, Henrik
    Persson, Frederik
    Ahluwalia, Tarunveer S.
    Hansen, Tine Willum
    Parving, Hans-Henrik
    Jacobsen, Peter Karl
    Rossing, Peter
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (07)
  • [27] Type 2 diabetes and cardiovascular disease in women
    Norhammar, A.
    Schenck-Gustafsson, K.
    DIABETOLOGIA, 2013, 56 (01) : 1 - 9
  • [28] Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study
    Olufade, Temitope
    Jiang, Like
    Israni, Rubeen
    Huang, Joanna
    Gosmanov, Aidar R.
    DIABETES OBESITY & METABOLISM, 2021, 23 (12) : 2741 - 2751
  • [29] Type 2 diabetes and cardiovascular disease in women
    A. Norhammar
    K. Schenck-Gustafsson
    Diabetologia, 2013, 56 : 1 - 9
  • [30] Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
    Gerstein, Hertzel C.
    Sattar, Naveed
    Rosenstock, Julio
    Ramasundarahettige, Chinthanie
    Pratley, Richard
    Lopes, Renato D.
    Lam, Carolyn S. P.
    Khurmi, Nardev S.
    Heenan, Laura
    Del Prato, Stefano
    Dyal, Leanne
    Branch, Kelley
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10) : 896 - 907